Skip to main content
Premium Trial:

Request an Annual Quote

Illumina Names Unit Leaders, Klemm Takes Reins at Predictive Bio, Becker Joins RainDance, and More

NEW YORK (GenomeWeb News) – Illumina has named Joel McComb senior VP and GM of Life Sciences, and Gregory Heath as senior VP and GM of the company’s Diagnostics Business unit.
McComb was president of Interventional Medicine at GE Healthcare, and he formerly was president and CEO of Innovadyne Technologies. He also was GM of Primary Care Diagnostics and director of corporate business development at Beckman Coulter.
Heath comes to the company from Roche Molecular Systems, where he was head of clinical genomics, senior VP of global product marketing, as well as senior VP of global marketing and business development.

Predictive Biosciences has named Peter Klemm president and CEO, as well as a director of the company. Klemm previously was CEO of GeneOhm Sciences, and he was CEO of JOMED and senior VP of R&D at Gruennenthal. He also was a senior scientist at Aventis and a post-doctoral fellow at the William Harvey Research Institute.

RainDance Technologies has appointed Stephen Becker to the posts of VP and chief commercial officer. Becker had been senior sales manager in field operations in the Americas for Agilent Technologies, and he was a director of gene and protein discovery and director of business support at GE Healthcare.

NuGEN Technologies has hired Beth Ladin to be VP of operations. Ladin previously was senior director of scientific operations for applied markets at Applied Biosystems, and she was a researcher at Henkel KGaA and a post-doctoral scientist at Washington University in St. Louis and at the University of Kansas.

Shobha Parthasarathi, a former researcher with Millennium Pharmaceuticals, has joined the North Carolina Biotechnology Center as development director of the center’s Business and Technology Group.

Gene Express has appointed James Mulshine to its scientific advisory board. Mulshine, a former oncologist at the National Cancer Institute, now is associate provost for research at Rush University Medical Center in Chicago. At NCI, he was head of the Intervention Section of the Cell and Cancer Biology Department, Division of Clinical Sciences. He is a member of the American Society of Clinical Oncology, American Association of Cancer Research, International Association for the Study of Lung Cancer, and the American Federation of Clinical Research.

Nathaniel Berlin, former director of the National Cancer Institute’s division of Cancer Biology and Diagnosis, died this week in Florida at the age of 87, The Washington Post reported today. Berlin also started and directed the Northwestern University Cancer Center and he was a professor of oncology and director of what became the Sylvester Comprehensive Cancer Center.

Promoted? Changing jobs? GenomeWeb wants to know. E-mail [email protected] to appear in PEOPLE, a weekly roundup of industry comings and goings.

The Scan

Study Links Genetic Risk for ADHD With Alzheimer's Disease

A higher polygenic risk score for attention-deficit/hyperactivity disorder is also linked to cognitive decline and Alzheimer's disease, a new study in Molecular Psychiatry finds.

Study Offers Insights Into Role of Structural Variants in Cancer

A new study in Nature using cell lines shows that structural variants can enable oncogene activation.

Computer Model Uses Genetics, Health Data to Predict Mental Disorders

A new model in JAMA Psychiatry finds combining genetic and health record data can predict a mental disorder diagnosis before one is made clinically.

Study Tracks Off-Target Gene Edits Linked to Epigenetic Features

Using machine learning, researchers characterize in BMC Genomics the potential off-target effects of 19 computed or experimentally determined epigenetic features during CRISPR-Cas9 editing.